Segments where we operate:
Instruments and consumables for biomolecule preparation&modification, purification and detection in
Cell biology

Relative market size based on customer demand is approximately Sweden 45%, Denmark 30%, Norway 15%, Finland 10%. These numbers may vary, depending on market segment.

Academic and health care accounts generally dominate the market for life science products in the Nordics, with pharma and biotech in some areas. Additionally, there are food, veterinary and environmental labs, as well as governmental institutes.

Potential customers are conducting promising research in new disciplines, such as the stem cell, genome editing and nanotechnology fields. Other important initiatives the coordination of biobanks, and investments in high throughput molecular bioscience.









Geography: three major scientific hubs are the regions of
Oslo region

Some key spots:

Sweden: Public and private labs in Stockholm, Göteborg, Linköping, Lund and Umeå add to the total picture.

Denmark: important pharma and biotech segment in Copenhagen, but the health sector also shows important activity in the cities of Aarhus, Aalborg, and Odense.

Norway: Being outside of the EU, this market is more isolated to the rest of the regions. However there is strong funding for medical and polar research. The health sector invests strongly in medical technology and IVD diagnostics. The fish industry also creates opportunity. Customers are mainly spread in the bigger university cities; Oslo, Bergen, Trondheim, Tromsø, and Stavanger.

Finland: Business is dominated in the geographical “golden” triangle of Helsinki, Turku and Tampere. The University of Oulu, with a strong protein chemistry tradition, and the University of Kuopio are also important sites.

LabLife Nordic AB

Rättarens väg 9
SE-182 34 Danderyd
+46 8 755 39 14